Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin for HER2-positive early breast cancer with poor early response to neoadjuvant dual-target therapy
ChiCTR2200060250Phase 2Completed
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in breast cancer, sponsored by Southwest Hospital of Army Medical University. Primary endpoint: pathological complete response rate. Started Jun 2022; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200060250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060250.